An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.-Reference-Cited by-同舟云学术

An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:TPS7076-TPS7076
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Boissel Nicolas¹,de Botton Stéphane²,Thomas Xavier G.³,Rao Ercole⁴,Bonnevaux Hélène⁵,Rubin-Carrez Chantal⁵,Guerif Stéphane⁵,Beys Eric⁵,Gosselin Alice⁵,Bauchet Anne-Laure⁶,Novikov Valery⁵,Fernandes Elma⁷,Wiederschain Dmitri⁸,Palatinsky Emanuel A.⁸,Hsu Karl⁸,Fraenkel Paula Goodman⁸

Affiliation:

1. Hôpital Saint-Louis, Paris, France;

2. INSERM U1170, Institut Gustave Roussy, Villejuif, France;

3. Centre Hospitalier Lyon Sud, Lyon, France;

4. Sanofi, Frankfurt Am Main, Germany;

5. Sanofi, Vitry-Sur-Seine, France;

6. Sanofi, Alfortville, France;

7. Sanofi, Bridgewater, NJ;

8. Sanofi, Cambridge, MA;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.15_suppl.TPS7076

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens;Statistics in Medicine;2021-07-14

2. Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics;Biometrics;2021-02-18

3. Bispecific antibodies in acute lymphoblastic leukemia therapy;Expert Review of Hematology;2020-11-01